Biotech News

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences (PLSE)Pulse Biosciences2026-07-29 11:00 ESTCompany update

HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 29, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-08-06 20:05 EST

Stock data

Close: 38.24 USD
Market cap: 1.68B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Related news

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Pulse Biosciences

Recent company news

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data